Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 1—January 2003

Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 4

Clinical failures of Streptococcus pneumoniae infection with levofloxacina

Risk factors
No. of cases
Age
Indication
Coexisting conditions
Prior FQ use
Yr
Ref.
Country
1b
58
Meningitis
HIV, splenectomy
NR
1999
62
USA
3
NR
RTI

Yes
1999
63
USA
1
63
CAP
COPD
No
1999
64
USA
1
50
CAP
COPD
No
2000
65
USA
1
84
CAP
COPD
Yes-Levo
2000
65
USA
1
53
HAP
none
No
2001
66
USA
7
39-83
(avg. 63)
4 CAP
3 AECB
COPD (5)
5/7
(4-Lev, 1-Mox)
2001
67
USA
1
37
CAP
none
No
1999
25
Canada
1b
66
CAP
COPD
Yes-Cip +
Lev
1999
25
Canada
1
80
AECB/CAP
COPD,
Yes-Cip
2001
25
Canada
1
64
CAP
none
No
2000
25
Canada
1
50
CAP
COPD
Yes-Lev
2001
68
USA
1b
79
CAP
none
NO
1999
69
USA
21







Clinical trials







13 (7 on 500 mg)
NR
AECB
COPD
No

70
Neth.
4
NR
CAP
NR
No

71
USA
24 (11)







Epidemiologic studies







16c
-
LRTI
COPD
Yes-Cip
1995-96
72
Canada
27d
-
LRTI
COPD (17)
Yes-Lev
1998-99
73
HK
43







Total 88 (74 on 500 mg) clinical/bacteriologic failures

aFQ, fluoroquinolone; NR, not reported; RTI, respiratory tract infection; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Lev, levofloxacin; Mox, moxifloxacin; HAP, hospital-acquired pneumonia; AECB, acute exacerbation of chronic bronchitis;
LRTI, lower respiratory tract infection; Cip, ciprofloxacin; Neth, the Netherlands; HK, Hong Kong.
bDeath.
c3 deaths.
d4 deaths.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO